Applying Regional Health Plan Best Practices in the Treatment of Eosinophilic Esophagitis

Mid-Atlantic AMCP Affiliate Educational Event
AMCP Mid-Atlantic
Jointly provided by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC.
Dinner is provided by Impact Education, LLC.

Partners for Advancing Clinical Education (PACE)     Impact Education, LLC
This activity is supported by an independent educational grant from Regeneron Pharmaceuticals and Sanofi.
Monday, May 20, 2024
5:30 PM - 6:30 PM ET - Registration and Reception
6:30 PM - 8:30 PM ET - Dinner and Presentation

2001 International Dr.
McLean, VA 22102
Dinner and drinks provided by Impact Education, LLC.

This CE program is intended for managed care and payer professionals from health plans, PBMs, integrated health systems, and other payer organizations. Others who wish to register may be added to a wait list based on venue capacity.
 Expert Faculty

The program will feature a multidisciplinary panel including an EoE clinical specialist and Mid-Atlantic Region managed care/payer experts.

  Who Should Attend?

This activity is designed to meet the educational needs of AMCP Mid-Atlantic affiliate members in the roles of pharmacy directors, clinical pharmacists, specialty pharmacists, medical directors, registered nurses, quality directors, and other pharmacists and physicians affiliated with various MCOs, health systems, and other payer organizations.

Participate in the pre-program survey: Click Here
The password to enter is: eoe

  Statement of Need/Program Overview

EoE is difficult to diagnose and treat, and as a result is associated with a high disease burden. Once payer decision makers recognize the disease has consequences and associated costs, they are interested in streamlining and standardizing its management to improve access to appropriate care. Managed care and payer professionals are well positioned to design and implement policies that have a considerable influence on patient access to appropriate care of EoE. Based on findings from previous initiatives, disease state baseline knowledge and awareness still needs to be improved and payers continue to need additional education to apply regional health plan best practices to improve EoE management. Incorporating an understanding of regional variances in EoE into healthcare strategies can ultimately lead to better outcomes for individuals with this condition while optimizing the utilization of healthcare resources and managing costs.

  Educational Objectives

At the conclusion of this activity, participants should be able to demonstrate improved ability to:
  • Discuss the diagnostic journey of patients with EoE and the importance of early diagnosis
  • Assess evidence-based treatment strategies and resources for optimal patient outcomes in EoE
  • Employ regional benefit design strategies that facilitate appropriate patient access to evidence-based treatment options for EoE
  • Implement collaborative regional payer/provider initiatives to improve the treatment of EoE

Date and Time
Monday, May 20, 2024
5:30 PM - 6:30 PM ET - Registration and Reception
6:30 PM - 8:30 PM ET - Dinner and Presentation

2001 International Dr.
McLean, VA 22102
Dinner and drinks provided by Impact Education, LLC.
Evidence-Based Diagnosis and Treatment of EoE
  • Patient journey to diagnosis
  • Disease overview
  • Treatment goals and key considerations
Improving Access to Timely Treatments
  • Access barriers to treatment options
  • Patient case presentation
Moderated Northwest Region Panel Discussion
  • Understanding regional perspectives on EoE
  • Regional opportunities to improve the quality of care
  • Collaborative opportunities and health plan best practices

  Accreditation Information
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education
PACE designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PACE designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-24-008-L01-P
Type of Activity: Application

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Fee Information
There is no fee for this educational activity.